Lung Cancer Clinical Trial
Official title:
Improving Management of Breathlessness in Patients With Lung Cancer
Many individuals with lung cancer experience debilitating breathlessness at some point
during the course of their illness. Unfortunately, few interventions exist to treat this
distressing symptom of cancer.
In this study, the investigators plan on recruiting individuals with lung cancer to
participate in a behavioral intervention to help relieve breathlessness. The principal
investigator of the study, Dr. Joseph Greer, is a licensed clinical psychologist who has
trained nurse practitioners in how to deliver the behavioral intervention. The nurse
practitioners will meet with patients diagnosed with lung cancer during their outpatient
oncology appointments, such as chemotherapy infusions, to review the behavioral skills that
may help with breathlessness. Specifically, the intervention includes education about the
relationship between breathlessness and the stress response as well as teaches patients
skills for breathing control and relaxation of the body.
For this single-group pilot study, the investigators will ask participants to provide
feedback about whether they found the intervention acceptable and effective. Participants
will also complete questionnaires about their physical and psychological symptoms before and
after the intervention in order to measure its effectiveness for treating breathlessness and
any distress related to breathlessness. The data from this study will help inform
improvements to the intervention in order to make it feasible and effective for treating
breathlessness in patients with lung cancer.
The purpose of this single-group pilot study is to test the feasibility and acceptability of
a cognitive-behavioral intervention for breathlessness in patients with lung cancer. Clinic
staff and research assistants will recruit potential participants in the outpatient oncology
department of the Massachusetts General Hospital. All participants will complete informed
consent procedures prior to initiating the study. The Dana-Farber/Partners Institutional
Review Board has approved the study methods.
Before beginning the first intervention session, enrolled participants will complete
questionnaires either on paper or online via a secure survey website. The questionnaire
takes about 15 minutes to complete and asks about the experience of breathlessness, mood and
anxiety symptoms, as well as general quality-of-life. Participants may refuse to answer any
questions that they do not wish to answer.
The study intervention involves two sessions with a nurse practitioner. Each session will
take approximately 30-45 minutes to complete.
- The first session will be scheduled around another oncology appointment, such
immediately before or after a clinic visit, or at the same time as a chemotherapy
infusion. During this session, participants will learn about several breathing and
relaxation exercises designed to relieve breathlessness. The nurse practitioner will
also provide handouts with directions for these exercises, an audio recording of the
relaxation techniques, and worksheets to encourage daily practice of these breathing
and relaxation exercises at home.
- The second session, which will take place 1-4 weeks after the first session, may also
be scheduled either before or after another oncology appointment. However, if this is
not possible, the second session may be completed over the telephone. During this
session, participants will meet with the same nurse practitioner to review the
behavioral exercises and to address any difficulties the participants may have
experienced in practicing the exercises.
Within two weeks after the second intervention session, a research assistant will contact
the participants either in person or over the telephone to complete the same questionnaires
administered before the intervention. Participants may choose to complete the follow-up
questionnaires on paper, over the telephone, or on a secure internet survey website. Also,
within two weeks after the second intervention session, the research assistant will conduct
a brief interview with the participants. Specifically, the research assistant will ask
questions about participants' perceived satisfaction with the behavioral intervention and
obtain feedback about how to improve the intervention. The interview will be audio-recorded
and take approximately 15-20 minutes to complete. These recordings and transcripts will only
be identified with a study number and stored electronically in a computer file that is
protected with a password only accessible to study staff. After completing the interview,
participants will be finished with the study.
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|